These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1487 related articles for article (PubMed ID: 15284307)

  • 1. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
    Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
    J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
    Naves-Díaz M; Passlick-Deetjen J; Guinsburg A; Marelli C; Fernández-Martín JL; Rodríguez-Puyol D; Cannata-Andía JB
    Nephrol Dial Transplant; 2011 Jun; 26(6):1938-47. PubMed ID: 20513773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.
    Danese MD; Kim J; Doan QV; Dylan M; Griffiths R; Chertow GM
    Am J Kidney Dis; 2006 Jan; 47(1):149-56. PubMed ID: 16377396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.
    Slinin Y; Foley RN; Collins AJ
    J Am Soc Nephrol; 2005 Jun; 16(6):1788-93. PubMed ID: 15814832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline.
    Noordzij M; Korevaar JC; Dekker FW; Boeschoten EW; Bos WJ; Krediet RT; Bossuyt PM; Geskus RB;
    Blood Purif; 2008; 26(3):231-7. PubMed ID: 18305386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access.
    Lacson E; Wang W; Hakim RM; Teng M; Lazarus JM
    Am J Kidney Dis; 2009 Jan; 53(1):79-90. PubMed ID: 18930570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.
    Gadallah MF; el-Shahawy M; Andrews G; Ibrahim M; Ramdeen G; Hanna D; Gorospe W; Morkos A; Abbassian M; Moles K
    Adv Perit Dial; 2001; 17():29-36. PubMed ID: 11510292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.
    Noordzij M; Korevaar JC; Bos WJ; Boeschoten EW; Dekker FW; Bossuyt PM; Krediet RT
    Nephrol Dial Transplant; 2006 Sep; 21(9):2513-20. PubMed ID: 16799173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A; Naderi AS
    Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disordered mineral metabolism is not a risk factor for loss of residual renal function in dialysis patients.
    Noordzij M; Voormolen NM; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT; Korevaar JC;
    Nephrol Dial Transplant; 2009 May; 24(5):1580-7. PubMed ID: 19155531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD.
    Menon V; Greene T; Pereira AA; Wang X; Beck GJ; Kusek JW; Collins AJ; Levey AS; Sarnak MJ
    Am J Kidney Dis; 2005 Sep; 46(3):455-63. PubMed ID: 16129207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism.
    Costa-Hong V; Jorgetti V; Gowdak LH; Moyses RM; Krieger EM; De Lima JJ
    Surgery; 2007 Nov; 142(5):699-703. PubMed ID: 17981190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need for better control of secondary hyperparathyroidism.
    Locatelli F
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
    Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
    Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
    Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H;
    Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.